12:00 AM
 | 
Apr 28, 2003
 |  BioCentury  |  Product Development

Cinacalcet's proposition

Although marketed vitamin D analogs are capable of suppressing the production of parathyroid hormone (PTH) to treat hyperparathyroidism (HPT), they can lead to episodes of abnormally increased levels of calcium and/or phosphorus. Looking to overcome these issues, Amgen Inc. and partner NPS Pharmaceuticals Inc. have been developing a more direct approach to treating the disease through the use of calcimimetics, compounds that target the calcium sense receptors (CaSRs).

Last week, AMGN (Thousand Oaks, Calif.) reported that cinacalcet (AMG 073) for secondary...

Read the full 406 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >